Pulse on MedTech: How the Industry is Reigniting Growth and Expanding Markets
April 30, 2026
11:00 AM – 12:00 PM
Join Ernst & Young LLP to explore key trends shaping the medtech industry.
Presented Ernst & Young LLP
Pulse on MedTech: How the Industry is Reigniting Growth and Expanding Markets
April 30, 2026
11:00 AM – 12:00 PM
Pulse on MedTech: How the Industry is Reigniting Growth and Expanding Markets
April 30, 2026
11:00 AM – 12:00 PM
As the medtech industry enters a pivotal phase of portfolio reshaping, companies are actively navigating renewed deal activity, selective IPO market reopening, and increased private equity investment. In this webinar, industry leaders will breakdown trends shaping medtech dealmaking. Throughout the webinar, panelists will also discuss the key findings from the EY Pulse of the MedTech Industry Report.
Throughout the session, they’ll highlight recent portfolio optimization moves as many companies continue to reposition themselves to take advantage of higher-growth end markets. Hear their perspectives on valuation dynamics, deal timing, and the strategic rationale driving both corporate and sponsor-led transactions. As a result, attendees will gain practical insights into the medtech dealmaking landscape.
Ultimately, understanding these trends and leadership perspectives will help you navigate the complexities of the industry and position you for success.
What You’ll Cover
Learn how M&A activity has evolved, assess the current public market outlook, while exploring the growing role of private equity in driving innovation and transactions.
- Earn your return: Total shareholder returns are strongly correlated with the successful (or failed) investment of capital into innovation and M&A.
- M&A integration is paramount: The successful integration of high-growth acquisitions is a competitive advantage. Focus on investing in commercial and R&D.
- Efficient organizational design and alignment: Evidence suggests that high-growth organizations thrive under a business unit–based operating model structure.
- Tariff mitigation strategy: Uncertainty persists in the global business environment. Companies must adapt to the shifting landscape with a multifunctional, tariff task force.
- Technology and artificial intelligence accelerate strategy: New markets are evolving with operational efficiencies to improve supply chains — front-office and back-office applications.
Date: Thursday, April 30, 2026
Time: 11:00 AM – 12:00 PM ET
Location: Online
RSVP now to uncover what’s next for medtech in today’s health care landscape.
Meet the Speakers
John Babitt, EY Global MedTech Leader (moderator)
John is an EY partner with over 30 years of experience in the life sciences and health care industry with a focus in MedTech, and a frequent lecturer and guest speaker at prominent life sciences conferences. He advises strategic and private equity life science clients on various projects, including M&A, supply chain, IT, and financial and tax considerations. John is a John previously served as the CFO of a publicly traded medical technology company and was responsible for all financial and operational aspects, including capital raising and negotiating and structuring numerous collaborations and licensing arrangements.
He received a BBA in Accounting, an MBA in Finance from the University of Miami and is a CPA licensed in Minnesota.
Finn Haley, Chief Business Development Officer, GE HealthCare
Finn Haley is GE HealthCare’s Chief Business Development Officer, responsible for driving GE HealthCare’s strategic business development goals and leading the business development team. Finn is a leader in healthcare mergers, acquisitions and strategy, with 23 years of experience spanning investment banking, Fortune 200 multinationals, and high-growth companies. Prior to joining GE HealthCare in April 2025, Finn was Senior Vice President of Corporate Development at Edwards Lifesciences, where he led a broad range of strategic transactions, including acquisitions, venture investments, strategic partnerships, divestitures and integrations.
Prior to joining Edwards Lifesciences, Finn worked for 3M Company, where he served as the Senior Strategy & Business Development Director of the Medical Division. While at 3M, Finn held positions of increasing responsibility, including Senior Director of Corporate Development and Global Business Line Manager for Wound Care. Prior to 3M, Finn worked in investment banking with Piper Jaffray’s healthcare coverage team and Duff & Phelps. Finn serves on the board of the Southern California Master Fund, a venture capital fund supporting local startups.
A strong advocate for education access, Finn has held board positions with organizations that help high-achieving students from low-income backgrounds attend college. Finn holds a Bachelor of Business Administration in Finance from the University of Wisconsin-Madison and a Master of Business Administration with honors from the University of Chicago Booth School of Business.
Eric Schantz, Vice President of Corporate Development, Medtronic
Eric Schantz is a Vice President of Corporate Development at Medtronic, focused on M&A in the cardiovascular portfolio, along with other strategic corporate transactions. Eric joined Medtronic in 2008 after several years as a sell-side equity research analyst covering cardiovascular, orthopedics, ophthalmology, aesthetics, and neuromodulation segments. Eric received a BS and MS in engineering from the University of Cincinnati, and an MBA from the University of Texas at Austin.
John Heinbigner, Partner, Life Sciences, EY-Parthenon, Ernst & Young LLP
As an EY partner with over 17 years of experience in the MedTech industry, John empowers Fortune 500 client executives and their M&A agenda; specializing in M&A-driven transformation, including buy-side diligence and carve-out transactions for strategics, and full enterprise sales for private equity clients. John received a BBA in Accounting from Saint John’s University, an MBA from the University of Minnesota and is a member of the AHA Twin Cities board and a CPA licensed in Minnesota.
Jay Zhu, Principal, MedTech Strategy, Transactions and Commercial, EY-Parthenon, Ernst & Young LLP
Eric Schantz is a Vice President of Corporate Development at Medtronic, focused on M&A in the cardiovascular portfolio, along with other strategic corporate transactions. Eric joined Medtronic in 2008 after several years as a sell-side equity research analyst covering cardiovascular, orthopedics, ophthalmology, aesthetics, and neuromodulation segments. Eric received a BS and MS in engineering from the University of Cincinnati, and an MBA from the University of Texas at Austin.
Hear From Us
Sign up to receive emails highlighting our upcoming events, early registration savings, and engagement opportunities for the medical technology community.